| Revenue growth | Revenue ~₹477 Cr, +13% QoQ; YoY lower, unquantified. |
|---|---|
| Margins | Adj EBITDA margin ~10%, up QoQ; lower YoY. |
| Order book | Q3-Q4 reload visibility improved; three new programs won. |
| Demand visibility | Reload orders improved for Q3-Q4; ADC destocking hurt payload demand. |
| Management confidence | Balanced; H2 recovery confident but unquantified. |
Growth
Revenue up ~13% QoQ, but YoY lower: Pharma CDMO -27%, API Plus +5%, Oligo +33.6%. Specialty chemicals -40.6% YoY.
Outlook
H2 FY27 YoY revenue and EBITDA growth expected, with no figures given. Specialty chemicals FY27 revenue guided to decline YoY.
Risks
Specialty chemicals now guided to decline in FY27. ADC customer destocking, USFDA remediation, and unassessed Surya Pake closure impact.
Last quarter's promises, checked
Delivered
- Seq Q2 rev growth → ₹477 Cr vs ₹422 Cr (+13% QoQ) (= BEAT)
- Seq EBITDA recovery → ~₹46 Cr vs ₹9.2 Cr (= BEAT)
Partly delivered
- Q2 Pharma CDMO 'significantly better' → YoY -38.7% narrowed to -27% (= PARTIAL)
- ADC payload on schedule Q2FY27 → destocking hurt demand; delivery unconfirmed (= PARTIAL)
Missed
- YoY comparability by end-H1 → still YoY lower; Spec Chem -40.6% (= MISS)
- FY27 margin near prior-year → ~10% adj, lower YoY (= MISS)
- FY27 Spec Chem H2-skewed growth → FY27 guided decline (= MISS)
Earnings Call Transcript filed with NSE, NSE: COHANCE. Summary written with AI assistance from the document.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹433.00
- Market cap
- ₹16,566 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 155.9×Sector 42.0×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Management Change
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Cohance Lifesciences Investor Presentation: Key Takeaways
Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.
Cohance Lifesciences Q2 FY27 Results: Net Profit ₹2.3 Cr, Down 96.5% YoY
Cohance Lifesciences Ltd reported revenue from operations of ₹476.6 Cr (-14.2% YoY) and net profit of ₹2.3 Cr (-96.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹2.3 Cr · -96.5% YoY
Cohance Lifesciences Adverse Business Impact
Cohance Lifesciences disclosed a TGPCB closure order halting manufacturing at its Suryapet site after an industrial accident. The financial impact cannot yet be quantified.
Cohance Lifesciences Board Meeting Date
Cohance Lifesciences will hold a board meeting on 6 November 2026 to approve Q2 and half-year results. The trading window stays closed until 9 November 2026.